Nanowire Biosensor Patent Allowed for Issuance to NanoIVD

Los Angeles, CA – NanoIVD, Inc announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the U.S. Patent for NanoIVD’s nanowire biosensor technology.
Spread the Word
Listed Under

Biosensor Cancer
Blood Test

• Medical Device Diagnostics

Los Angeles - California - US

Aug. 29, 2012 - PRLog -- Los Angeles, CA  – NanoIVD, Inc announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the U.S. Patent for NanoIVD’s nanowire biosensor technology. As a result, NanoIVD expects that the patent will be issued sometime this year. The patent application serial no. 12/632,661 (“MICROFLUIDIC-BASED LAB-ON-A-TEST CARD FOR A POINT-OF-CARE ANALYZER”) was filed December 7, 2009 for the United States, EU, Korea, China, and Japan, and claimed the benefit of U.S. provisional patent application serial no. 61/120,253 (“INTEGRATED SEMICONDUCTOR-NANOSENSOR ANALYSIS SYSTEM”) filed December 5, 2008.

The technology enables a cost-effective and commercially scalable nanowire biosensor for near-patient or point-of-care patient testing with real-time electric sensing of multiple target markers in a single sample. Qualitative and quantitative tests can be performed from a single-use biosensor chip embedded in a disposable test cartridge. No PCR or tag molecule (i.e. radioactive isotope, fluorophore, magnetic beads, enzyme, etc.) is needed.    
"The granting of this patent is a critical accomplishment in recognition of the unique qualities of NanoIVD’s nanowire biosensor technology, said Sunnie Park Kim, NanoIVD’s Chief Executive Officer. Kim added, “Because early detection can improve the cure rate and quality-of-life for cancer patients, bravely fighting the battle, the biosensor is an important milestone achievement for NanoIVD and serves as springboard for commercial development of simple blood tests that quantitatively measures key biomarkers of cancer pathways and progression identified by NanoIVD’s algorithm from thousands of clinical data.”

NanoIVD’s pancreatic, liver, thyroid, prostate, and other cancer tests are intended to aid healthcare professionals in:  
•    appropriate treatment selection that reduces patient risk and increases effectiveness
•    estimated patient prognosis ahtlr and treatment management
•    detection and diagnosis before cancer symptoms occur  

In addition to cancer, the nanowire biosensor technology can be used for testing a variety of other conditions such as Alzheimer’s, diabetes, and coronary artery diseases, as well as infectious diseases; interestingly NanoIVD’s research on cancer pathways also revealed significant effects to genes for insulin receptor, insulin, apolipoprotein B (associated with coronary heart disease), and amyloid (Alzheimer’s disease).  

About NanoIVD
NanoIVD is a nonpublic Delaware C corporation established in November 2008. The company actively works on new discoveries and innovations. The company has proprietary technologies for a point-of-care analyzer and single-use test cartridge system capable of minimally invasive health monitoring, early disease detection, and treatment-effectiveness monitoring using small amounts of blood. The technologies can achieve high sensitivity and specificity—single or multiplex genomic, proteomic, and cellular target(s) detection—in a single test run with versatile, real-time detection and rapid results.  

NanoIVD is headquartered at Good Samaritan Hospital Medical Building (Los Angeles, CA). It also utilizes the California NanoSystems Institute (CNSI) at UCLA, Nanoelectronics Research Facility (NRF) at UCLA, and the Kavli Nanoscience Institutes (KNI) at Caltech.

Statements about our future expectations, including development and regulatory plans, and all other statements in this press release, other than historical facts, are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. If and when used herein, the words "may," "will," "should," "anticipate," "believe," "intend," "plan," "expect," "estimate," "approximate," and similar expressions, as they relate to us or our business or management, are intended to identify such forward-looking statements. These statements involve risks and uncertainties related to market acceptance of and competition for our technologies, growth strategies, operating performance, industry trends, and other risks and uncertainties inherent in our business.  We undertake no obligation to update publicly any forward-looking statement.

Direct inquiries to:
Jennifer Campbell
NanoIVD, Inc.
Tel: 424.634.2652
Email:*** Email Verified
Phone:(424) 634-2652
Tags:Nanotechnology, Patent, Biosensor Cancer, Blood Test
Industry:Medical Device Diagnostics
Location:Los Angeles - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share